\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{The Human Genome Revolution}{section.1.1}% 3
\BOOKMARK [3][-]{section*.4}{The First Human Genome Sequence}{subsection.1.1.1}% 4
\BOOKMARK [3][-]{section*.5}{Expectations of Genomics}{subsection.1.1.1}% 5
\BOOKMARK [2][-]{subsection.1.1.2}{Technologies to Enable Genetics Research}{section.1.1}% 6
\BOOKMARK [3][-]{section*.6}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.2}% 7
\BOOKMARK [3][-]{section*.7}{Microarrays and Quantitative Technologies}{subsection.1.1.2}% 8
\BOOKMARK [3][-]{section*.8}{Massively Parallel ``Next Generation'' Sequencing Technologies}{subsection.1.1.2}% 9
\BOOKMARK [4][-]{section*.9}{Established Sequencing Technologies}{section*.8}% 10
\BOOKMARK [4][-]{section*.10}{Emerging Sequencing Technologies}{section*.8}% 11
\BOOKMARK [3][-]{section*.11}{Bioinformatics to Enable Genomics Research}{subsection.1.1.2}% 12
\BOOKMARK [2][-]{subsection.1.1.3}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 13
\BOOKMARK [2][-]{subsection.1.1.4}{Cancer Genomes}{section.1.1}% 14
\BOOKMARK [3][-]{section*.12}{The Cancer Genome Atlas Project}{subsection.1.1.4}% 15
\BOOKMARK [3][-]{section*.13}{The International Cancer Genome Consortium}{subsection.1.1.4}% 16
\BOOKMARK [3][-]{section*.14}{Subpopulation and Cell Line projects}{subsection.1.1.4}% 17
\BOOKMARK [2][-]{subsection.1.1.5}{Genomic Cancer Medicine}{section.1.1}% 18
\BOOKMARK [3][-]{section*.15}{Cancer Genes and Driver Mutations}{subsection.1.1.5}% 19
\BOOKMARK [3][-]{section*.16}{Personalised or Precision Cancer Medicine}{subsection.1.1.5}% 20
\BOOKMARK [4][-]{section*.17}{Molecular Diagnostics and Pan-Cancer Medicine}{section*.16}% 21
\BOOKMARK [4][-]{section*.18}{Gene Expression Signatures and Biomarkers}{section*.16}% 22
\BOOKMARK [3][-]{section*.19}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.5}% 23
\BOOKMARK [4][-]{section*.20}{Targeting Oncogenic Driver Mutations}{section*.19}% 24
\BOOKMARK [4][-]{section*.21}{Tissue Specificity and Genetics Background Effects}{section*.19}% 25
\BOOKMARK [4][-]{section*.22}{Network Biology, Network Medicine, and Polypharmacology}{section*.19}% 26
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 27
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 28
\BOOKMARK [3][-]{section*.23}{Synthetic Lethal Drug Design}{subsection.1.2.1}% 29
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 30
\BOOKMARK [3][-]{section*.24}{Functional Genetics}{subsection.1.2.2}% 31
\BOOKMARK [4][-]{section*.25}{Conditional and Induced Essentiality}{section*.24}% 32
\BOOKMARK [4][-]{section*.26}{Functional Redundancy}{section*.24}% 33
\BOOKMARK [3][-]{section*.27}{Evolutionary and Developmental Biology}{subsection.1.2.2}% 34
\BOOKMARK [4][-]{section*.28}{Genetic Robustness and Network ``Re-wiring''}{section*.27}% 35
\BOOKMARK [3][-]{section*.29}{Cancer and Translational Biology}{subsection.1.2.2}% 36
\BOOKMARK [4][-]{section*.30}{Non-Oncogene Addiction}{section*.29}% 37
\BOOKMARK [2][-]{subsection.1.2.3}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 38
\BOOKMARK [3][-]{section*.31}{Synthetic Lethal Pathways}{subsection.1.2.3}% 39
\BOOKMARK [3][-]{section*.32}{Experimental Inference}{subsection.1.2.3}% 40
\BOOKMARK [3][-]{section*.33}{Models and Computational Detection}{subsection.1.2.3}% 41
\BOOKMARK [2][-]{subsection.1.2.4}{The Potential of Synthetic Lethality for Anti-Cancer Medicine}{section.1.2}% 42
\BOOKMARK [3][-]{section*.34}{Rationale of Exploiting Synthetic Lethality in Cancers}{subsection.1.2.4}% 43
\BOOKMARK [4][-]{section*.35}{Indirect Targeting and Tumour Suppressor Genes}{section*.34}% 44
\BOOKMARK [4][-]{section*.36}{Synthetic Interactions and Gene Dosage}{section*.34}% 45
\BOOKMARK [4][-]{section*.37}{Homology and Indirect Targeting for Anti-Cancer Specificity}{section*.34}% 46
\BOOKMARK [2][-]{subsection.1.2.5}{Prior Studies on Synthetic Lethality}{section.1.2}% 47
\BOOKMARK [3][-]{section*.38}{Experimental Studies of Synthetic Lethality}{subsection.1.2.5}% 48
\BOOKMARK [4][-]{section*.39}{RNA interference in Eukaryotes}{section*.38}% 49
\BOOKMARK [3][-]{section*.40}{Examples of Clinical Impact}{subsection.1.2.5}% 50
\BOOKMARK [3][-]{section*.41}{High-throughput Screening for Synthetic Lethality}{subsection.1.2.5}% 51
\BOOKMARK [4][-]{section*.42}{Examples of High-throughput Synthetic Lethal Screens}{section*.41}% 52
\BOOKMARK [3][-]{section*.43}{Computational Prediction of Synthetic Lethality}{subsection.1.2.5}% 53
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 54
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and it's Biological Functions}{section.1.3}% 55
\BOOKMARK [3][-]{section*.44}{Cytoskeleton}{subsection.1.3.1}% 56
\BOOKMARK [3][-]{section*.45}{Extracellular and Tumour Micro-Environment}{subsection.1.3.1}% 57
\BOOKMARK [3][-]{section*.46}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 58
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 59
\BOOKMARK [3][-]{section*.47}{Stomach Cancers}{subsection.1.3.2}% 60
\BOOKMARK [3][-]{section*.48}{Breast Cancers}{subsection.1.3.2}% 61
\BOOKMARK [3][-]{section*.49}{Role in Carcinogensis and Tumourigenesis}{subsection.1.3.2}% 62
\BOOKMARK [3][-]{section*.50}{Role in Tumour Progression and Metastasis}{subsection.1.3.2}% 63
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 64
\BOOKMARK [3][-]{section*.51}{Prevalence}{subsection.1.3.3}% 65
\BOOKMARK [3][-]{section*.52}{Screening, Diagnosis, and Management}{subsection.1.3.3}% 66
\BOOKMARK [3][-]{section*.53}{Stomach Cancer}{subsection.1.3.3}% 67
\BOOKMARK [3][-]{section*.54}{Breast Cancer}{subsection.1.3.3}% 68
\BOOKMARK [3][-]{section*.55}{``Second Hit'' Model and Gene Inactivation Mechanisms}{subsection.1.3.3}% 69
\BOOKMARK [2][-]{subsection.1.3.4}{Somatic CDH1 Mutations in Sporadic Cancers}{section.1.3}% 70
\BOOKMARK [3][-]{section*.56}{Rate of Mutations}{subsection.1.3.4}% 71
\BOOKMARK [3][-]{section*.57}{Co-occuring mutations}{subsection.1.3.4}% 72
\BOOKMARK [2][-]{subsection.1.3.5}{Models of CDH1 loss in cell lines}{section.1.3}% 73
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 74
\BOOKMARK [0][-]{chapter.2}{Methods, Techniques, and Resources}{}% 75
\BOOKMARK [1][-]{subsection.2.0.1}{Network Theory}{chapter.2}% 76
\BOOKMARK [2][-]{subsection.2.0.2}{Biological Networks}{subsection.2.0.1}% 77
\BOOKMARK [3][-]{section*.58}{Public Data and Software Packages}{subsection.2.0.2}% 78
\BOOKMARK [3][-]{section*.59}{Computational Tools for Biological Research}{subsection.2.0.2}% 79
\BOOKMARK [4][-]{section*.60}{High Performance and Parallel Computing in Biology}{section*.59}% 80
\BOOKMARK [3][-]{section*.61}{Gene Expression Analysis and Statistical Challenges in Bioinformatics}{subsection.2.0.2}% 81
\BOOKMARK [4][-]{section*.62}{Hypothesis Testing and Multiple Comparisons Procedures}{section*.61}% 82
\BOOKMARK [4][-]{section*.63}{Candidate Triage and Integration with Experimental Data}{section*.61}% 83
\BOOKMARK [3][-]{section*.64}{Mathematical Challenges in Bioinformatics}{subsection.2.0.2}% 84
\BOOKMARK [4][-]{section*.65}{Graph Theory, Systems, and Network Biology}{section*.64}% 85
\BOOKMARK [4][-]{section*.66}{Matrix Operations and Pathway ``Metagenes''}{section*.64}% 86
\BOOKMARK [2][-]{subsection.2.0.3}{Data Sources}{subsection.2.0.1}% 87
\BOOKMARK [0][-]{chapter.3}{Synthetic Lethal Analysis of Gene Expression Data}{}% 88
\BOOKMARK [1][-]{section.3.1}{Abstract}{chapter.3}% 89
\BOOKMARK [1][-]{section.3.2}{Aims and Significance}{chapter.3}% 90
\BOOKMARK [1][-]{section.3.3}{Background}{chapter.3}% 91
\BOOKMARK [1][-]{section.3.4}{Background}{chapter.3}% 92
\BOOKMARK [1][-]{section.3.5}{Sourcing TCGA data}{chapter.3}% 93
\BOOKMARK [1][-]{section.3.6}{Quality checking}{chapter.3}% 94
\BOOKMARK [1][-]{section.3.7}{Global Synthetic Lethality}{chapter.3}% 95
\BOOKMARK [1][-]{section.3.8}{CDH1 Analysis with Subgroups}{chapter.3}% 96
\BOOKMARK [1][-]{section.3.9}{Cell Line Analysis}{chapter.3}% 97
\BOOKMARK [1][-]{section.3.10}{Mutation, Copy Number, and Methylation}{chapter.3}% 98
\BOOKMARK [1][-]{section.3.11}{ANOVA of Expression Predictors}{chapter.3}% 99
\BOOKMARK [1][-]{section.3.12}{Mutation Analysis, Pathway Expression, and Metagene Synthetic Lethality}{chapter.3}% 100
\BOOKMARK [1][-]{section.3.13}{Data clean up, gene SL, and pathway SL}{chapter.3}% 101
\BOOKMARK [1][-]{section.3.14}{Overview of Challenges}{chapter.3}% 102
\BOOKMARK [1][-]{section.3.15}{Comparison of gene SL predictions and siRNA screen candidates}{chapter.3}% 103
\BOOKMARK [1][-]{section.3.16}{Permutation or Re-Sampling of genes for pathway enrichment.}{chapter.3}% 104
\BOOKMARK [1][-]{section.3.17}{Comparison of candidate SL Pathways}{chapter.3}% 105
\BOOKMARK [1][-]{section.3.18}{Future Directions}{chapter.3}% 106
\BOOKMARK [1][-]{section.3.19}{Hub Genes}{chapter.3}% 107
\BOOKMARK [1][-]{section.3.20}{Metagene pathway expression}{chapter.3}% 108
\BOOKMARK [1][-]{section.3.21}{Metagene synthetic lethality}{chapter.3}% 109
\BOOKMARK [1][-]{section.3.22}{Replication in stomach cancer}{chapter.3}% 110
\BOOKMARK [1][-]{section.3.23}{Important Results}{chapter.3}% 111
\BOOKMARK [0][-]{chapter.4}{Pathway Structure of Synthetic Lethal Genes}{}% 112
\BOOKMARK [1][-]{section.4.1}{Abstract}{chapter.4}% 113
\BOOKMARK [1][-]{section.4.2}{Background}{chapter.4}% 114
\BOOKMARK [1][-]{section.4.3}{Reactome Network structure and Information Centrality as a measure of gene essentiality}{chapter.4}% 115
\BOOKMARK [1][-]{section.4.4}{Synthetic lethal genes in synthetic lethal pathways}{chapter.4}% 116
\BOOKMARK [1][-]{section.4.5}{Methods}{chapter.4}% 117
\BOOKMARK [2][-]{subsection.4.5.1}{Sourcing graph structure data}{section.4.5}% 118
\BOOKMARK [2][-]{subsection.4.5.2}{Constructing pathway subgraphs}{section.4.5}% 119
\BOOKMARK [2][-]{subsection.4.5.3}{Centrality Measures}{section.4.5}% 120
\BOOKMARK [2][-]{subsection.4.5.4}{upstream and downstream gene detection}{section.4.5}% 121
\BOOKMARK [2][-]{subsection.4.5.5}{permutation analysis}{section.4.5}% 122
\BOOKMARK [1][-]{section.4.6}{Centrality and connectivity of synthetic lethal genes}{chapter.4}% 123
\BOOKMARK [1][-]{section.4.7}{Upstream or downstream synthetic lethal candidates}{chapter.4}% 124
\BOOKMARK [1][-]{section.4.8}{Hierachical approach}{chapter.4}% 125
\BOOKMARK [1][-]{section.4.9}{Discussion}{chapter.4}% 126
\BOOKMARK [1][-]{section.4.10}{Conclusion}{chapter.4}% 127
\BOOKMARK [0][-]{chapter.5}{Simulation and Modeling of Synthetic Lethal Pathways}{}% 128
\BOOKMARK [1][-]{section.5.1}{Abstract}{chapter.5}% 129
\BOOKMARK [1][-]{section.5.2}{Background}{chapter.5}% 130
\BOOKMARK [1][-]{section.5.3}{Simulations and Modelling Synthetic Lethality in Expression Data}{chapter.5}% 131
\BOOKMARK [1][-]{section.5.4}{Developing a Synthetic Lethal detection methodology}{chapter.5}% 132
\BOOKMARK [2][-]{subsection.5.4.1}{Testing Multivariate Normal Simulation of Synthetic lethality}{section.5.4}% 133
\BOOKMARK [2][-]{subsection.5.4.2}{Receiver Operating Characteristic Curves}{section.5.4}% 134
\BOOKMARK [2][-]{subsection.5.4.3}{Simulated Expression Heatmaps}{section.5.4}% 135
\BOOKMARK [2][-]{subsection.5.4.4}{Replication Simulation Heatmap}{section.5.4}% 136
\BOOKMARK [1][-]{section.5.5}{Simulation of synthetic lethality in graph structures}{chapter.5}% 137
\BOOKMARK [2][-]{subsection.5.5.1}{Developing a multivariate normal expression from graph structures}{section.5.5}% 138
\BOOKMARK [2][-]{subsection.5.5.2}{Simulations over simple graph structures}{section.5.5}% 139
\BOOKMARK [3][-]{section*.67}{Performance}{subsection.5.5.2}% 140
\BOOKMARK [3][-]{section*.68}{Synthetic lethality across graph stuctures}{subsection.5.5.2}% 141
\BOOKMARK [3][-]{section*.69}{Performance with inhibition links}{subsection.5.5.2}% 142
\BOOKMARK [3][-]{section*.70}{Performance with 20,000 genes}{subsection.5.5.2}% 143
\BOOKMARK [2][-]{subsection.5.5.3}{Simulations over pathway-based graphs}{section.5.5}% 144
\BOOKMARK [2][-]{subsection.5.5.4}{Comparing methods}{section.5.5}% 145
\BOOKMARK [3][-]{section*.71}{SLIPT and Chi-Squared}{subsection.5.5.4}% 146
\BOOKMARK [4][-]{section*.72}{Correlated query genes}{section*.71}% 147
\BOOKMARK [3][-]{section*.73}{Correlation}{subsection.5.5.4}% 148
\BOOKMARK [3][-]{section*.74}{Linear models}{subsection.5.5.4}% 149
\BOOKMARK [2][-]{subsection.5.5.5}{Developing a linear model predictor of synthetic lethality}{section.5.5}% 150
\BOOKMARK [3][-]{section*.75}{Linear models}{subsection.5.5.5}% 151
\BOOKMARK [3][-]{section*.76}{Polynomial models}{subsection.5.5.5}% 152
\BOOKMARK [3][-]{section*.77}{Conditioning}{subsection.5.5.5}% 153
\BOOKMARK [3][-]{section*.78}{SLIPTv2}{subsection.5.5.5}% 154
\BOOKMARK [1][-]{section.5.6}{Significance}{chapter.5}% 155
\BOOKMARK [1][-]{section.5.7}{Future Directions}{chapter.5}% 156
\BOOKMARK [1][-]{section.5.8}{Conclusion}{chapter.5}% 157
\BOOKMARK [0][-]{chapter.6}{Discussion}{}% 158
\BOOKMARK [0][-]{chapter.7}{Conclusion}{}% 159
\BOOKMARK [0][-]{chapter.7}{References}{}% 160
